ALFA Finder| Revenue growth | 10.6% YoY in Q3; 9.4% YoY in 9M FY26. |
|---|---|
| Margins | Gross margin expanded 184bps to 58.1% due to soft raw material costs. |
| Order book | U.S. order book at $220 million plus. |
| Demand visibility | Strong U.S. order book; seasonal uptick in cough/cold/pain segments. |
| Management confidence | High; optimistic on U.S. market and European expansion. |
Growth
Revenue grew 10.6% YoY to ₹754.4cr; EBITDA up 23.2% to ₹160.7cr; PAT up 8.2% to ₹113.7cr.
Outlook
Targeting ₹4,000cr revenue milestone by FY28/29; aggressive U.K. filings; active acquisition search in Europe.
Risks
Rx price erosion in U.K./U.S.; geopolitical uncertainties; macroeconomic challenges in Rest of World markets.
Earnings Call filed with NSE, NSE: MARKSANS. Summary written with AI assistance from the document.
Marksans Pharma Ltd: key numbers
- Share price
- ₹308.30
- Market cap
- ₹13,973 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 25.0×Sector 43.8×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 19.06%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marksans Pharma Ltd
All →Marksans Pharma Earnings Call Transcript: Key Takeaways
Headline growth is strong: revenue up 30.5% to ₹940 Cr and EBITDA margin 22.8%, above the 21–22% guide. Sequentially, margin, gross margin and PAT all fell, and growth is partly acquired.
Marksans Pharma Employee Stock Options
Marksans Pharma allotted 56,250 equity shares to employee stock option grantees under its 2024 scheme. Shares were issued on exercise of vested options.
Marksans Pharma Results Update
Marksans Pharma reported Q2FY27 revenue of ₹940 crore and H1FY27 PAT of ₹303 crore. EBITDA grew 48% to a record ₹214 crore in the quarter.
Marksans Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue ₹940cr (+30.5% YoY), EBITDA ₹214cr at 22.8% margin (+274bps), PAT ₹143.5cr (+44.8%). H1 PAT ₹303cr; net cash ₹1,095cr; Europe front-end being built.
Marksans Pharma Q2 FY27 Results: Net Profit ₹143.5 Cr, Up 44.8% YoY
Marksans Pharma Ltd reported revenue from operations of ₹940.2 Cr (+30.5% YoY) and net profit of ₹143.5 Cr (+44.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹143.5 Cr · +44.8% YoY
Marksans Pharma Board Meeting Date
Marksans Pharma scheduled its Board meeting for November 4, 2026, to approve Q1/H1 unaudited results. No material decision has been taken yet.